Blockchain Registration Transaction Record

BIOT Tapped to Advance CelSiege's IN01 Cancer Immunotherapy in Asia

BIOT partners with CelSiege to advance IN01 cancer immunotherapy in Japan and China, targeting lung cancer and other solid tumors.

This collaboration positions BIOT as a key facilitator in bringing a novel cancer immunotherapy to two of the world’s largest and most medically underserved oncology markets. With lung cancer remaining the leading cause of cancer death globally, the introduction of IN01—a therapeutic vaccine targeting EGF—could offer a new treatment avenue for patients with squamous non-small cell lung cancer and potentially other cancers. The partnership leverages Japan and China’s substantial patient populations and advanced clinical research infrastructure, potentially accelerating development and commercialization. If successful, this initiative could expand therapeutic options, stimulate local biotech investment, and contribute to addressing significant unmet medical needs in oncology across Asia.